Thomas G. Wiggans, Director at Jasper Therapeutics, Inc. (JSPR), bought 30,000 shares at $0.60 ($18K) on 2023-11-17, disclosed to the SEC on 2023-11-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.60 | 10,000 | $6K | 32.8% |
| 2 | $0.60 | 10,000 | $6K | 32.8% |
| 3 | $0.63 | 10,000 | $6K | 34.4% |
| Total | $0.61 avg | 30,000 | $18K | 100% |
| Filing → |
| JSPR | BUY | 2023-11-22 | $6K | — | Filing → |
| PRDS | BUY | 2022-12-07 | $14K | — | Filing → |
| PRDS | BUY | 2022-12-05 | $39K | — | Filing → |